Cognitive Deficit Clinical Trial
Official title:
Effect of Vortioxetine on Cognitive Symptoms in Patients With
Research goals:
1. Examination of the relationship between the use of vortioxetine and cognitive efficacy
in patients with schizophrenia.
2. Examination of the association between the use of vortioxetine and the presence
depressive symptoms, physical and social anhedonia in patients with the disease from
schizophrenia.
3. Examining the association between vortioxetine use and quality of life
(functional recovery) in patients with schizophrenia
Expected results (hypotheses)
1. Patients with schizophrenia treated with additional therapy vortioxetine will show
better cognitive achievement in memory (short-term and long-term), attention, logical
reasoning and reasoning, speed of information processing, processing of visual and sound
information, language and speech in relation to patients without additional
intervention.
2. Patients with schizophrenia treated with additional therapy vortioxetine will have a
less pronounced presence of depressive symptoms, physical and social anhedonia in
relation to untreated patients with additional vortioxetine therapy.
3. Patients with schizophrenia who were treated with additional therapy vortioxetine will
have a better quality of life, ie. better functional recovery
In the first phase of the research, the development of the research protocol and obtaining it
will be done of his approval.
The second phase of the research will include patients with schizophrenia disorders based on
inclusive and exclusive criteria and a study will be conducted procedure. In the third phase
of the research, the obtained results are processed and analyzed.
The content of the dissertation will include an introduction, a goal with hypotheses,
methods, results, discussion, conclusions and literature. In the introduction, in addition to
current knowledge about schizophrenia and vortioxetine, it will be pointed out cognition
problem in patients with schizophrenia.
It will be defined and explained hypotheses and research objectives. In the chapter dedicated
to methodology, the number of respondents and a description will be presented study concepts,
presentation of statistical methods used for data processing The presentation of the results
obtained by this study will be presented textually, tabularly and using charts. The obtained
results will be commented and evaluated in the Discussion. Recent literature will be used
Randomization 1:1 will divide 120 patients with schizophrenia into two groups, each group
into 3 subgroups. One group of 60 patients (who are on monotherapy antipsychotics: new
generations: 20 patients will be on olanzapine, 20 patients on risperidone and 20 patients on
aripiprazole) will receive vortioxetine and the other control group of 60 patients (who is
also on monotherapy with new antipsychotics generations: 20 patients will be on olanzapine,
20 patients on risperidone and 20 patients on aripiprazole) will not receive vortioxetine.
Vortioxetine will be given in 10 mg dose (which can be reduced by 5 mg if needed in case of
poor tolerability)
1. Initial examination:
International mini neuropsychiatric interview (M.I.N.I.) publicly available, works
doctor General questionnaire - designed by a doctor Positive and negative syndrome
scales (PANSS) are publicly available, by a doctor The Calgary Depression Scale for
Schizophrenia (CDSS) is publicly available, it works doctor World Health Organization
for Quality of Life (WHOQOL-BREF) publicly available, works doctor Chapman (social
anhedonia and physical anhedonia) - publicly available, works doctor Wechsler WAIS IV
(subtests: numerical memory test; encryption test symbols) - available at Naklada Slap,
Zagreb, HR, by a clinical psychologist
Screening tests:
1. Mini-mental state (MMSE) or Folstein test - publicly available, by a doctor
2. Montreal Cognitive Assessment (MoCA) - publicly available, by a physician
2. At the end of the second month:
International mini neuropsychiatric interview (M.I.N.I.) publicly available, works
doctor Mini-mental state (MMSE) or Folstein test - publicly available, by a doctor
Montreal Cognitive Assessment (MoCA) - publicly available, by a doctor
3. At the end of the third month:
International mini neuropsychiatric interview (M.I.N.I.) publicly available, works doctor
Positive and negative syndrome scales (PANSS) are publicly available, by a doctor The Calgary
Depression Scale for Schizophrenia (CDSS) is publicly available, it works doctor World Health
Organization for Quality of Life (WHOQOL-BREF) publicly available, works doctor Chapman
(social anhedonia and physical anhedonia) - publicly available, works doctor Wechsler WAIS IV
(subtests: numerical memory test; encryption test)
- Available at Naklada Slap, Zagreb, HR, by a clinical psychologist Screening tests: a)
Mini-mental state (MMSE) or Folstein test - public
available, works doctor b) Montreal Cognitive Assessment (MoCA) - publicly available, by a
doctor It is expected: improvement of cognitive functions in relation to the initial
examination
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04961112 -
Evaluating the Efficacy of Cranial Electrotherapy Stimulation in Mitigating Anxiety-induced Cognitive Deficits
|
N/A | |
Completed |
NCT03695614 -
Cognitive Remediation Therapy for Participants With Late-Life Schizophrenia
|
N/A | |
Active, not recruiting |
NCT05879562 -
Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO
|
N/A | |
Completed |
NCT03286439 -
Recovery After Medical or Surgical Treatment
|
||
Recruiting |
NCT04251624 -
Investigating the Use of Goal Management Therapy in Improving Cognitive Functioning in Public Safety Personnel With PTSD
|
N/A | |
Not yet recruiting |
NCT02763397 -
Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (NbM) in Patients With Parkinson's Disease
|
N/A | |
Recruiting |
NCT04051528 -
Do Combinatorial Training Lead to Better Cognition and Daily Participation in TBI Persons With Cognitive Impairments
|
N/A | |
Recruiting |
NCT03036319 -
Patient-Centered NeuroRehabilitation (PCN)
|
N/A | |
Recruiting |
NCT05251454 -
Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.
|
N/A | |
Completed |
NCT05063669 -
Cognitive Intervention in Attention Deficit and Hyperactivity Disorder
|
N/A | |
Completed |
NCT02964221 -
Cognitive Changes After Major Joint Replacement
|
N/A | |
Not yet recruiting |
NCT05605366 -
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02214342 -
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment
|
N/A | |
Terminated |
NCT03032471 -
Swiss SOS MoCA - DCI Study
|
||
Recruiting |
NCT04204239 -
Validation Study SCOBES-AR
|
||
Withdrawn |
NCT04457271 -
Goal Management Training in Individuals With PTSD
|
N/A | |
Terminated |
NCT03034109 -
Transcranial Direct Current Stimulation (tDCS) in Post-Stroke Working Memory Deficits
|
N/A | |
Recruiting |
NCT05802680 -
Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation
|
N/A | |
Active, not recruiting |
NCT02847403 -
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
|
Phase 3 | |
Withdrawn |
NCT04654130 -
Neurofeedback Effectiveness Trial in PTSD
|
N/A |